Geriatric vision loss due to cataracts, macular degeneration, and glaucoma.

The major causes of impaired vision in the elderly population of the United States are cataracts, macular degeneration, and open-angle glaucoma. Cataracts and macular degeneration usually reduce central vision, especially reading and near activities, whereas chronic glaucoma characteristically attacks peripheral vision in a silent way, impacting balance, walking, and driving. Untreated, these visual problems lead to issues with regard to taking medications, keeping track of finances and personal information, walking, watching television, and attending the theater, and often create social isolation. Thus, visually impaired individuals enter nursing homes 3 years earlier, have twice the risk of falling, and have 4× the risk of hip fracture. Consequently, many elderly with low vision exercise greater demands on community services. With the prospect of little improvement and sustained visual loss, in the face of poor tolerance of low-vision services and not accepting magnification as the only way to read, clinical depression is common. In many instances, however, early and accurate diagnosis can result in timely treatment and can preserve quality of life. This review will look at current diagnostic and therapeutic considerations. Currently, about 20.5 million people in the United States have cataracts. The number will reach 30 million by 2020. About 1.75 million Americans currently have some form of macular degeneration, and the number is estimated to increase to 2.95 million in 2020. Approximately 2.2 million Americans have glaucoma, and by 2020 that number is estimated to be close to 3.4 million people. It is projected that by 2030 there will be 72.1 million seniors. With some overlap of the above 3 groups conservatively estimated (if you add the 2030 cataract group to the macular degeneration and glaucoma groups), then about 1 in 2 senior individuals by 2030 may have some significant ocular disease, which could account for about 50% of the healthcare budget for the elderly.

[1]  S. Gedde,et al.  Review of results from the Tube Versus Trabeculectomy Study , 2010, Current opinion in ophthalmology.

[2]  David J. Apple,et al.  Posterior capsule opacification. , 1992, Survey of ophthalmology.

[3]  S. Fisher,et al.  Age-related macular degeneration is associated with an unstable ARMS2 (LOC387715) mRNA , 2008, Nature Genetics.

[4]  D. Apple,et al.  Surgical prevention of posterior capsule opacification. Part 2: Enhancement of cortical cleanup by focusing on hydrodissection. , 2000, Journal of cataract and refractive surgery.

[5]  J J Anderson,et al.  Impaired Vision and Hip Fracture , 1989, Journal of the American Geriatrics Society.

[6]  P. Rosenfeld,et al.  Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. , 2011, Ophthalmology.

[7]  Denise S. Kim,et al.  Differences in rates of glaucoma among Asian Americans and other racial groups, and among various Asian ethnic groups. , 2011, Ophthalmology.

[8]  C. Margo,et al.  Cataract Surgery Among Veterans 65 Years of Age and Older: Analysis of National Veterans Health Administration Databases , 2010, American journal of medical quality : the official journal of the American College of Medical Quality.

[9]  N. Powe,et al.  Synthesis of the literature on visual acuity and complications following cataract extraction with intraocular lens implantation. Cataract Patient Outcome Research Team. , 1994, Archives of ophthalmology.

[10]  K. Hoffer Biometry of 7,500 cataractous eyes. , 1980, American journal of ophthalmology.

[11]  V. Ourednik,et al.  Neural Stem/Progenitor Cells Initiate the Formation of Cellular Networks That Provide Neuroprotection by Growth Factor‐Modulated Antioxidant Expression , 2008, Stem cells.

[12]  R. Guymer,et al.  C-reactive protein levels and complement factor H polymorphism interaction in age-related macular degeneration and its progression. , 2010, Ophthalmology.

[13]  Douglas R. Anderson,et al.  The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group. , 1998, American journal of ophthalmology.

[14]  Jennifer I. Lim,et al.  A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. , 2001, Archives of ophthalmology.

[15]  Kuldev Singh,et al.  Early aggressive intraocular pressure lowering, target intraocular pressure, and a novel concept for glaucoma care. , 2008, Survey of ophthalmology.

[16]  N. Mamalis,et al.  Three‐year clinical comparison of 3‐piece AcrySof and SI‐40 silicone intraocular lenses , 2002, Journal of cataract and refractive surgery.

[17]  K. Schulman,et al.  Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. , 2010, Archives of ophthalmology.

[18]  D. R. Anderson,et al.  Glaucoma: the damage caused by pressure. XLVI Edward Jackson memorial lecture. , 1989, American journal of ophthalmology.

[19]  H. Hayashi,et al.  Anterior capsule contraction and intraocular lens dislocation in eyes with pseudoexfoliation syndrome , 1998, The British journal of ophthalmology.

[20]  T. Wong,et al.  Dietary omega-3 fatty acid and fish intake in the primary prevention of age-related macular degeneration: a systematic review and meta-analysis. , 2008, Archives of ophthalmology.

[21]  R. Klein,et al.  Ten-year incidence and progression of age-related maculopathy: The Beaver Dam eye study. , 2002, Ophthalmology.

[22]  C. Sorenson,et al.  Anti-vascular endothelial growth factor therapy and renal thrombotic microangiopathy. , 2011, Archives of ophthalmology.

[23]  J. Menikoff,et al.  Prophylaxis of endophthalmitis with topical povidone-iodine. , 1991, Ophthalmology.

[24]  L. Leape,et al.  The appropriateness of use of coronary artery bypass graft surgery in New York State. , 1993, JAMA.

[25]  S. Masket,et al.  Bacterial endophthalmitis prophylaxis for cataract surgery: an evidence-based update. , 2002, Ophthalmology.

[26]  A. Sommer,et al.  The prevalence of blindness and visual impairment among nursing home residents in Baltimore. , 1995, The New England journal of medicine.

[27]  C. Alpers,et al.  VEGF inhibition and renal thrombotic microangiopathy. , 2008, The New England journal of medicine.

[28]  A. Reidy,et al.  Extracapsular cataract extraction compared with small incision surgery by phacoemulsification: a randomised trial , 2001, The British journal of ophthalmology.

[29]  R. Hitchings,et al.  Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma. , 1994, Ophthalmology.

[30]  M. Leyland,et al.  Multifocal versus monofocal intraocular lenses in cataract surgery: a systematic review. , 2003, Ophthalmology.

[31]  L. Aiello,et al.  RISKS OF INTRAVITREOUS INJECTION: A COMPREHENSIVE REVIEW , 2004, Retina.

[32]  K. D. Eichenbaum,et al.  Comparing dynamic contour tonometry to Goldmann and hand-held tonometry in normal, ocular hypertension, and glaucoma populations , 2007, Annals of ophthalmology.

[33]  Paul P. Lee,et al.  Longitudinal rates of cataract surgery. , 2006, Archives of ophthalmology.

[34]  C. Lowder,et al.  Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. , 2011, Archives of ophthalmology.

[35]  E. Halm,et al.  Revisiting the Appropriateness of Carotid Endarterectomy , 2003, Stroke.

[36]  P. Yoder,et al.  Toric intraocular lens implantation: 100 consecutive cases , 2002, Journal of cataract and refractive surgery.

[37]  R. Klein,et al.  Lutein and zeaxanthin in the diet and serum and their relation to age-related maculopathy in the third national health and nutrition examination survey. , 2001, American journal of epidemiology.

[38]  Beth T. Stalvey,et al.  Older drivers and cataract: driving habits and crash risk. , 1999, The journals of gerontology. Series A, Biological sciences and medical sciences.

[39]  M. Mulvihill,et al.  The prevalence of eye disease in nursing home and non-nursing home geriatric populations. , 1999, Archives of gerontology and geriatrics.

[40]  Chris A. Johnson,et al.  The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. , 2002 .

[41]  B. Prum,et al.  The advanced glaucoma intervention study (AGIS): 7. the relationship between control of intraocular pressure and visual field deterioration , 2000 .

[42]  S. Asrani,et al.  Large Diurnal Fluctuations in Intraocular Pressure Are an Independent Risk Factor in Patients With Glaucoma , 2000, Journal of glaucoma.

[43]  M. Tinetti,et al.  Risk factors for falls among elderly persons living in the community. , 1988, The New England journal of medicine.

[44]  P. Jong Prevalence of age-related macular degeneration in the United States. , 2004 .

[45]  E. E. Hartmann,et al.  The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. , 2002, Archives of ophthalmology.

[46]  Glenn J Jaffe,et al.  Ranibizumab and bevacizumab for neovascular age-related macular degeneration. , 2011, The New England journal of medicine.

[47]  Britta Lundqvist,et al.  Ten-year longitudinal visual function and Nd: YAG laser capsulotomy rates in patients less than 65 years at cataract surgery. , 2010, American journal of ophthalmology.

[48]  R. Klein,et al.  Prevalence of age-related macular degeneration in a population-based sample of Hispanic people in Arizona: Proyecto VER. , 2005, Archives of ophthalmology.

[49]  Young H. Kwon,et al.  Novel drug delivery systems for glaucoma , 2011, Eye.

[50]  G. Naumann,et al.  Differential gene expression in pseudoexfoliation syndrome. , 2005, Investigative ophthalmology & visual science.

[51]  R. E. Smith,et al.  Propionibacterium acnes isolated from explanted intraocular lens in pseudophakic bullous keratopathy. , 1989, Cornea.

[52]  R. Klein,et al.  Prevalence of age-related macular degeneration in 4 racial/ethnic groups in the multi-ethnic study of atherosclerosis. , 2006, Ophthalmology.

[53]  M. Kahook,et al.  Assessment of bleb morphologic features and postoperative outcomes after Ex-PRESS drainage device implantation versus trabeculectomy. , 2011, American journal of ophthalmology.

[54]  R. Klein,et al.  Prevalence of age-related maculopathy. The Beaver Dam Eye Study. , 1992, Ophthalmology.

[55]  P. Gouras,et al.  Drusenoid maculopathy in rhesus monkeys: autofluorescence, lipofuscin and drusen pathogenesis , 2008, Graefe's Archive for Clinical and Experimental Ophthalmology.

[56]  S. West,et al.  Epidemiology of risk factors for age-related cataract. , 1995, Survey of ophthalmology.

[57]  M. C. Leske,et al.  Prevalence of open-angle glaucoma among adults in the United States. , 2004, Archives of ophthalmology.

[58]  N. Camp,et al.  A Variant of the HTRA1 Gene Increases Susceptibility to Age-Related Macular Degeneration , 2006, Science.

[59]  S. Masket,et al.  Late complications with intraocular lens dislocation after capsulorhexis in pseudoexfoliation syndrome. , 2002, Journal of cataract and refractive surgery.

[60]  B. Nan,et al.  Rates of nonexudative and exudative age-related macular degeneration among Asian American ethnic groups. , 2011, Investigative ophthalmology & visual science.

[61]  C. Owsley,et al.  Impact of cataract surgery on self‐reported visual difficulties: Comparison with a no‐surgery reference group , 2003, Journal of cataract and refractive surgery.

[62]  T. Sheidow,et al.  Triamcinolone acetonide as adjunctive treatment to verteporfin in neovascular age-related macular degeneration: a prospective randomized trial. , 2007, Ophthalmology.

[63]  R. Klein,et al.  Ten-year incidence of age-related maculopathy and smoking and drinking: the Beaver Dam Eye Study. , 2002, American journal of epidemiology.

[64]  Li Wang,et al.  Effect of decentration of wavefront-corrected intraocular lenses on the higher-order aberrations of the eye. , 2005, Archives of ophthalmology.

[65]  H. Jampel Target pressure in glaucoma therapy. , 1997, Journal of glaucoma.

[66]  Shan C. Lin,et al.  Endoscopic and Transscleral Cyclophotocoagulation for the Treatment of Refractory Glaucoma , 2008, Journal of glaucoma.

[67]  R. Klein,et al.  Prevalence and risk indicators of visual impairment and blindness in Latinos: the Los Angeles Latino Eye Study. , 2004, Ophthalmology.

[68]  C. Margo,et al.  AGE-RELATED MACULAR DEGENERATION, ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS, AND SHORT-TERM MORTALITY: A Postmarketing Medication Safety and Surveillance Study , 2011, Retina.

[69]  J. Douketis,et al.  Safety of continuing warfarin therapy during cataract surgery: a systematic review and meta-analysis. , 2009, Thrombosis research.

[70]  S. Gupta,et al.  Role of early trabeculectomy in primary open-angle glaucoma in the developing world , 2007, Eye.

[71]  C. Puliafito,et al.  Cystoid macular edema, retinal detachment, and glaucoma after Nd:YAG laser posterior capsulotomy. , 1991, American journal of ophthalmology.

[72]  N. Congdon,et al.  Prevalence of cataract and pseudophakia/aphakia among adults in the United States. , 2004, Archives of ophthalmology.

[73]  N. Soumittra,et al.  Association of non-synonymous single nucleotide polymorphisms in the LOXL1 gene with pseudoexfoliation syndrome in India , 2008, Molecular vision.

[74]  George A. Williams,et al.  Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. , 2007, Archives of ophthalmology.

[75]  Q. Nguyen,et al.  Fluocinolone acetonide intravitreal sustained release device – a new addition to the armamentarium of uveitic management , 2007, International journal of nanomedicine.

[76]  J. Beiser,et al.  The Ocular Hypertension Treatment Study Topical Medication Delays or Prevents Primary Open-angle Glaucoma in African American Individuals , 2004 .

[77]  R. Klein,et al.  Relation of smoking to the incidence of age-related maculopathy. The Beaver Dam Eye Study. , 1998, American journal of epidemiology.

[78]  D. Kripke,et al.  Comparison of the nocturnal effects of once-daily timolol and latanoprost on intraocular pressure. , 2004, American journal of ophthalmology.

[79]  W. Culbertson,et al.  Femtosecond laser-assisted cataract surgery , 2010, Current opinion in ophthalmology.

[80]  R. Klein,et al.  The Los Angeles Latino Eye Study: design, methods, and baseline data. , 2004, Ophthalmology.

[81]  B. Rosner,et al.  Progression of age-related macular degeneration: prospective assessment of C-reactive protein, interleukin 6, and other cardiovascular biomarkers. , 2005, Archives of ophthalmology.

[82]  S. Hahn,et al.  Evaluation of practice patterns for the care of open-angle glaucoma compared with claims data: the Glaucoma Adherence and Persistency Study. , 2007, Ophthalmology.

[83]  C. Margo,et al.  Substance Use Disorder and the Risk of Open-angle Glaucoma , 2011, Journal of glaucoma.

[84]  Akira Negi,et al.  LOC387715/HTRA1 variants in polypoidal choroidal vasculopathy and age-related macular degeneration in a Japanese population. , 2007, American journal of ophthalmology.

[85]  A. Coleman,et al.  Intraocular Pressure Fluctuation : A Risk Factor for Visual Field Progression at Low Intraocular Pressures in the Advanced Glaucoma Intervention Study , 2008 .

[86]  Cynthia Owsley,et al.  Impact of cataract surgery on motor vehicle crash involvement by older adults. , 2002, JAMA.

[87]  A. Vasavada,et al.  Anterior capsule relationship of the AcrySof intraocular lens optic and posterior capsule opacification: a prospective randomized clinical trial. , 2004, Ophthalmology.

[88]  N. Powe,et al.  Correction: Inaccurate classification and information reported in a study of statin use and sepsis in patients with chronic kidney disease. , 2008, JAMA.

[89]  Douglas R. Anderson,et al.  Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group. , 1998, American journal of ophthalmology.

[90]  W. Smiddy Economic considerations of macular edema therapies. , 2011, Ophthalmology.

[91]  J. Ott,et al.  Complement Factor H Polymorphism in Age-Related Macular Degeneration , 2005, Science.

[92]  R. Klein,et al.  The economic burden of major adult visual disorders in the United States. , 2006, Archives of ophthalmology.

[93]  D. Friedman,et al.  An evidence-based assessment of risk factors for the progression of ocular hypertension and glaucoma. , 2004, American journal of ophthalmology.

[94]  F. Ferris,et al.  The relationship of dietary lipid intake and age-related macular degeneration in a case-control study: AREDS Report No. 20. , 2007, Archives of ophthalmology.

[95]  D. Roth,et al.  The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing. , 2011, Ophthalmology.

[96]  Philip J Rosenfeld,et al.  Ranibizumab for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.